Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evomela conditioning for ASCT in multiple myeloma
NCT01660633Phase 2Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Dec 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EVOMELA in multiple myeloma (MM), sponsored by Acrotech Biopharma Inc. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Mucositis Severity according to World Health Organization Scoring System and 2 more. Started Dec 2012; status: completed.
02
Drugs
EVOMELA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01660633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01660633.